Month: May 2026

Australian biotech HaemaLogiX spoke to Scrip about its approach to the multiple myeloma space, and how it differentiates itself with new drug targets.

“There are a lot of drugs for multiple myeloma. It’s, in some ways, a very crowded space,” said CEO Chris Baldwin. “But we’re the only ones who are targeting KMA/LMA. Part of that is due to the extensive patent portfolio that we’ve established and developed over the course of the last 20 years. It means that when we come into the market, we have a very strong differentiator compared to anything out there,” Baldwin continued.

Read the full story here. 

Fredrik Frejd, Chief Scientific Officer at Affibody, talked to Drug Discovery World about how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. 

The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024.  

This commercial validation has sparked intense interest from both pharmaceutical companies and investors, with multiple billion-dollar acquisitions in the radiopharmaceutical space signalling confidence in the therapeutic approach. 

Read the full story here. 

CuraCell was recently featured in a wide ranging article in Labiotech on TIL therapy. 

While many TIL developers are looking to treat melanoma first, the Swedish biotech is the first to take on prostate cancer. Its prime candidate CC-38 is being developed to address immunologically ‘cold’ solid tumors.

“While CAR-T therapies are clinically established in hematologic cancers, their efficacy in solid tumors – particularly immunologically cold tumors – remains unproven due to challenges such as limited tumor infiltration, antigen heterogeneity, and complex multi-step manufacturing processes. TIL therapies overcome these barriers by using naturally tumour-adapted T cells that can effectively infiltrate the tumour microenvironment and, through their polyclonal nature, recognize multiple tumour antigens, thereby reducing immune escape and improving outcomes in heterogeneous cancers,” said Jonas Båtelson, CEO and co-founder of CuraCell. 

For more information on the TIL development landscape, read the whole article here.